Spirovant

About:

Spirovant Sciences is developing novel gene therapies for cystic fibrosis and other pulmonary diseases.

Twitter/X: spirovant

Top Investors: Small Business Innovation Research, Cystic Fibrosis Foundation

Description:

Spirovant is focused on changing the course of cystic fibrosis and other pulmonary diseases. Their gene therapy technologies are designed to overcome the historical barriers that have prevented effective genetic treatments for cystic fibrosis.

Total Funding Amount:

$4.73M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Pausa, Sachsen, Germany

Founded Date:

2016-01-01

Contact Email:

info(AT)spirovant.com

Founders:

Eric Yuen, Joan Lau

Number of Employees:

11-50

Last Funding Date:

2019-01-24

IPO Status:

Private

Industries: